Revdofilimab Biosimilar – Anti-TNFRSF4 mAb – Research Grade

Description of Revdofilimab Biosimilar - Anti-TNFRSF4 mAb - Research Grade

Introduction

Revdofilimab biosimilar is a highly promising therapeutic antibody that targets TNFRSF4, a key receptor involved in immune regulation. This monoclonal antibody (mAb) is a research grade version of the original Revdofilimab, which has shown great potential in treating various autoimmune and inflammatory diseases. In this article, we will delve into the structure, activity, and potential applications of this biosimilar.

Structure of Revdofilimab Biosimilar

Revdofilimab biosimilar is a recombinant humanized IgG1 mAb that specifically binds to TNFRSF4. It is composed of two heavy chains and two light chains, each with a unique amino acid sequence. The heavy chains contain a constant region (Fc) and a variable region (Fab), while the light chains only have a variable region. The Fc region is responsible for the effector functions of the antibody, such as complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC). The Fab region, on the other hand, is responsible for binding to the target receptor, TNFRSF4.

Activity of Revdofilimab Biosimilar

Revdofilimab biosimilar exerts its activity by binding to TNFRSF4, a cell surface receptor that is expressed on various immune cells, including T cells, B cells, and dendritic cells. Upon binding, the antibody blocks the interaction between TNFRSF4 and its ligand, OX40L. This, in turn, inhibits the activation of T cells and the production of pro-inflammatory cytokines, such as IL-2 and IFN-γ. Additionally, the Fc region of the antibody can trigger ADCC, leading to the elimination of TNFRSF4-expressing cells.

Therapeutic Target: TNFRSF4

TNFRSF4, also known as OX40, is a member of the tumor necrosis factor receptor superfamily. It is a co-stimulatory receptor that plays a crucial role in regulating T cell activation and differentiation. TNFRSF4 is upregulated on activated T cells and has been implicated in the pathogenesis of various autoimmune and inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Therefore, targeting TNFRSF4 with Revdofilimab biosimilar can potentially modulate the immune response and provide therapeutic benefits in these conditions.

Applications of Revdofilimab Biosimilar

Revdofilimab biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of autoimmune and inflammatory diseases. In a phase II clinical trial, the original Revdofilimab demonstrated significant clinical improvement in patients with rheumatoid arthritis, with a favorable safety profile. The biosimilar version is expected to have similar efficacy and safety, making it a potential alternative to the original drug.

Moreover, Revdofilimab biosimilar has the potential to be used in combination with other therapies. For instance, it can be combined with anti-TNF agents to enhance their efficacy or with immune checkpoint inhibitors to overcome resistance. Additionally, the antibody can also be used as a research tool to study the role of TNFRSF4 in various diseases and to develop new treatment strategies.

Conclusion

In conclusion, Revdofilimab biosimilar is a highly promising therapeutic antibody that targets TNFRSF4, a key receptor involved in immune regulation. Its unique structure and mechanism of action make it a potential treatment option for various autoimmune and inflammatory diseases. With ongoing clinical trials and further research, Revdofilimab biosimilar has the potential to improve the lives of patients suffering from these conditions.

SDS-PAGE for Revdofilimab Biosimilar – Anti-TNFRSF4 mAb

Revdofilimab Biosimilar – Anti-TNFRSF4 mAb on SDS-PAGE under non-reducing (left figure) and reducing (right figure) conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is superior than 90 %.